Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26749541)
Watch
English
Ramucirumab: Boon or bane
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
0 references
title
Ramucirumab: Boon or bane
(English)
0 references
author name string
Priya Tiwari
series ordinal
1
0 references
language of work or name
English
0 references
publication date
September 2016
0 references
published in
Journal of the Egyptian National Cancer Institute
1 reference
stated in
PubMed
volume
28
0 references
issue
3
0 references
page(s)
133-40
0 references
cites work
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab-associated fistula formation in postoperative colorectal cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The structural basis for the function of two anti-VEGF receptor 2 antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2016.03.001
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/J.JNCI.2016.03.001
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3331450
OpenCitations bibliographic resource ID
3331450
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3331450
PubMed publication ID
27025409
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3331450
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
